Researchers Find Recipients of Johnson & Johnson Covid Vaccine are 3.5X More Likely Than General Population to Develop Rare, Deadly Blood Clotting Condition in Brain

A stunning new study that was conducted by researchers from the Mayo Clinic in Rochester, Minnesota has concluded that the Johnson & Johnson Covid vaccine increases the risk of developing a rare and deadly blood clotting condition in the brain.

The study, which was published on Monday in the Journal of the American Medical Association (JAMA), found that recipients of the one-shot J&J vaccine are 3.5 times more likely (8.65 per 100,000) to develop cerebral venous sinus thrombosis (CVST) when compared to the general population (2.34 per 100,000).

“The overall age- and sex-adjusted CVST incidence [within the general population before the Covid-19 outbreak] was 2.34 per 100 000 person-years. Age-adjusted CVST rates for female and male individuals were 2.46 per 100 000 PY and 2.34 per 100 000 PY, respectively.

The overall incidence rate of post–Ad26.COV2.S [Johnson & Johnson] vaccination CVST was 8.65 per 100 000 PY at 15 days, 5.02 per 100 000 PY  at 30 days, and 1.73 per 100 000 PY at 92 days (Table 2).”

Researchers compared public health data from before the Covid-19 outbreak to reports of verified cases of CVST that were recorded in the CDC’s Vaccine Adverse Events Reporting System (VAERS).

The study also found that women were most at risk after taking the J&J jab, checking in at a whopping 5.1 times more likely to develop the deadly condition.

They accounted for over 70% of the new cases of CVST that were directly linked to J&J in VAERS.

Read More